Work

Muvalaplin: A Novel Oral Therapy for Targeted Reduction of Plasma Lipoprotein(a)

Year: 2026

Type: article

Study design: Systematic Review

Source: Cardiovascular & Haematological Disorders - Drug Targets

DOI: 10.2174/011871529x418596251201142137

Authors: Monica Botros, Michelle Tiji, Richard Lange

Institution: Texas Tech University Health Sciences Center

Language: English

Topic: Lipoproteins and Cardiovascular Health

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7125828281

FWCI: 13.03

Cites: 44

Cited by: 2

Related to: